Granuloma annulare

disease

On this page

Summary

Granuloma annulare (MONDO:0006554) is a disease and 10 clinical trials. Top therapeutic interventions include cravacitinib and abrocitinib. A subtype of dermatitis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

Clinical trials: 10

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	granuloma annulare
Mondo ID	MONDO:0006554
EFO	EFO:1000704
MeSH	D016460
DOID	DOID:3777
ICD-10-CM	L92.0
ICD-11	1925637202
NCIT	C3470
SNOMED CT	65508009
UMLS	C0085074
MedGen	88319
Is cancer (heuristic)	no

Also known as: granuloma annulare

Disease family

This is a subtype of dermatitis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › integumentary system disorder › skin disorder › dermatitis › granuloma annulare

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

No approved or late-stage (phase ≥3) drug is indicated for this disease; the following are in earlier-phase trials only.

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Abrocitinib.

Clinical trials & evidence

Clinical trials

Clinical trials: 10.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	4
PHASE2	2
PHASE1	2
PHASE4	1
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03630198	PHASE4	COMPLETED	Pain Outcomes Following Intralesional Corticosteroid Injections
NCT05650736	PHASE2	ACTIVE_NOT_RECRUITING	Janus Kinase Inhibition in Granuloma Annulare
NCT00129428	PHASE1/PHASE2	COMPLETED	Ultraviolet B (UVB) Light Therapy in the Treatment of Skin Conditions With Altered Dermal Matrix
NCT06725264	PHASE2	WITHDRAWN	Tyrosine Kinase 2 (TYK2) for GA and CS
NCT03910543	PHASE1	COMPLETED	Open-label Trial of Tofacitinib in Cutaneous Sarcoidosis and Granuloma Annulare
NCT05580042	PHASE1	COMPLETED	Study to Evaluate the Safety and Tolerability of AC-1101 Topical Gel in Patients with Granuloma Annulare
NCT00476697	Not specified	TERMINATED	UVA1 Light for Scleroderma and Similar Conditions
NCT00720980	Not specified	COMPLETED	Granuloma Annulare Treated With Rifampin, Ofloxacin, and Minocycline Combination Therapy
NCT05472636	Not specified	COMPLETED	Evaluation of 41 Cases of Pediatric Granuloma Annulare
NCT07428954	Not specified	COMPLETED	Using Artificial Intelligence to Help Doctors Identify Different Skin Conditions and Improve Patient Care

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CRAVACITINIB	4	3
ABROCITINIB	4	1

Drugs: Cravacitinib, Abrocitinib